Brokerages Set Sotera Health (NASDAQ:SHC) Target Price at $16.08

Shares of Sotera Health (NASDAQ:SHC - Get Free Report) have received an average recommendation of "Moderate Buy" from the six ratings firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $16.08.

Several research analysts have recently issued reports on SHC shares. Barclays lowered their price target on shares of Sotera Health from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. The Goldman Sachs Group assumed coverage on Sotera Health in a research report on Friday, December 6th. They issued a "neutral" rating and a $14.00 target price for the company. Royal Bank of Canada reissued an "outperform" rating and set a $17.00 price target on shares of Sotera Health in a research note on Thursday, November 21st. Finally, Citigroup upped their price objective on Sotera Health from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Blue Trust Inc. lifted its stake in shares of Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock valued at $25,000 after buying an additional 1,140 shares in the last quarter. Quarry LP purchased a new stake in shares of Sotera Health during the fourth quarter worth $28,000. True Wealth Design LLC bought a new position in shares of Sotera Health in the third quarter worth $32,000. GAMMA Investing LLC grew its position in shares of Sotera Health by 37.5% in the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company's stock valued at $56,000 after purchasing an additional 1,121 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of Sotera Health by 37.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock valued at $82,000 after purchasing an additional 1,640 shares in the last quarter. 91.03% of the stock is owned by institutional investors.

Sotera Health Stock Performance

NASDAQ SHC remained flat at $13.52 on Friday. The company's stock had a trading volume of 864,109 shares, compared to its average volume of 796,593. The business has a 50 day moving average price of $13.45 and a 200-day moving average price of $14.56. The company has a market cap of $3.83 billion, a PE ratio of 54.08 and a beta of 1.91. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.